• Research in Australia shows marijuana helps with chronic pain and insomnia
  • The rules around getting prescriptions for medicinal cannabis
  • A quick look at the winners and losers of ASX weed stocks


Sufferers of chronic pain and insomnia have the most to benefit from consuming marijuana, according to new research published in the Journal of American Medical Association (JAMA) last week.

The research shows “significant improvements” in quality of life for people with those conditions, with the positive effects being “largely sustained” over time.

The analysis was conducted in 3,148 people in Australia, who were prescribed medical cannabis for treating certain eligible conditions.

Eight wellbeing indicators were tested, with patients being asked to rate their wellness on a scale of 0-100 at different stages of treatment.

The eight categories were general health, bodily pain, physical functioning, role limitations, mental health, emotional role limitations, social functioning and vitality.

Results from the survey overwhelmingly showed that marijuana helped with the conditions of patients, while adverse side effects were “rarely serious”.

“These findings suggest that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions,” said the researchers in the study.


How do we get our hands on medical cannabis?

In 2016, the Australian Federal Government legalised the sale and use of medicinal cannabis, which jump-started the domestic industry.

But its use only exploded in 2019, with around 3% of Aussies reportedly using some form of cannabis to treat chronic pain and mental health issues.

While the TGA regulates access, most medicinal cannabis products in Australia are considered to be unapproved medicines – which means they have not been assessed by the TGA for safety, quality or effectiveness.

If you’re wondering whether medicinal cannabis is right for your condition, the TGA advises that your first step is to have a conversation with your doctor.

There are currently no restrictions imposed by the TGA on the conditions for which a doctor may prescribe cannabis.

But an application to the TGA would have to be made for the prescription, which generally takes around two working days for approval.

For privacy reasons, the TGA does not publish a list of Authorised Prescribers who have been authorised to supply medicinal cannabis products.


Psychedelics for mental health

Further progress was made in March, when Australia became the first country in the world to recognise psychedelics as medicine after the TGA approved psychedelic substances used in magic mushrooms and MDMA.

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by authorised psychiatrists in Australia for treating certain mental health conditions.

Under the new guidance, the TGA says it will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder (PTSD), and psilocybin for the treatment-resistant depression.

Since that announcement, dozens of clinics with both online and physical locations have sprouted, offering psychedelic-based psychotherapy sessions.


To ASX Weed Stocks ….

Here’s how the ASX weed stocks have performed, sorted by winners over the past week.

Code Company Price % Year % Six Month % Month % Week Market Cap
CAN Cann Group Ltd 0.19 -42.42 -17.39 18.75 18.75 $65,984,627
LGP Little Green Pharma 0.19 -40.32 0.00 2.78 8.82 $53,796,569
EPN Epsilon Healthcare 0.02 -48.57 -30.77 -5.26 5.88 $5,406,372
ECS ECS Botanics Holding 0.02 -13.64 -9.52 -5.00 5.56 $21,027,883
BOT Botanix Pharma Ltd 0.09 3.66 37.10 -11.46 4.94 $114,894,380
HGV Hygrovest Limited 0.06 -1.64 -14.29 13.21 1.69 $13,797,239
ZLD Zelira Therapeutics 0.92 -22.13 -9.41 -11.17 0.55 $10,325,911
CTV Colortv Limited 0.01 -20.00 0.00 0.00 0.00 $1,236,985
RNO Rhinomed Ltd 0.08 -52.24 -27.27 -8.05 0.00 $22,857,576
WFL Wellfully Limited 0.01 -85.48 -55.00 -18.18 0.00 $4,436,497
EOF Ecofibre Limited 0.17 -55.26 -38.18 0.00 0.00 $62,858,619
LV1 Live Verdure Ltd 0.15 -34.09 -14.71 -12.12 0.00 $12,290,063
ROO Roots Sustainable 0.01 -90.00 -75.00 -25.00 0.00 $773,540
EXL Elixinol Wellness 0.02 -64.00 -37.93 -10.00 0.00 $7,109,226
TSN The Sust Nutri Grp 0.01 -90.71 -90.71 -23.53 0.00 $1,829,918
WOA Wide Open Agricultur 0.33 -42.48 -7.14 96.97 0.00 $42,016,576
RGI Roto-Gro Intl Ltd 0.22 0.00 0.00 0.00 0.00 $4,333,920
IRX Inhalerx Limited 0.05 -47.06 -16.67 0.00 0.00 $8,539,513
CPH Creso Pharma Ltd 0.02 -68.63 -30.43 45.45 0.00 $34,192,651
AC8 Auscann Grp Hlgs Ltd 0.04 -34.43 0.00 0.00 0.00 $17,621,884
MDC Medlab Clinical Ltd 6.60 -48.84 -20.00 0.00 0.00 $15,071,113
IHL Incannex Healthcare 0.11 -76.92 -60.38 -8.70 0.00 $158,701,036
IDT IDT Australia Ltd 0.08 -36.92 -11.83 20.59 0.00 $19,986,269
EVE EVE Health Group Ltd 0.00 -20.00 0.00 0.00 0.00 $5,274,483
CGB Cann Global Limited 0.02 -22.22 0.00 0.00 0.00 $5,436,345
WNX Wellnex Life Ltd 0.06 -37.89 -19.18 -13.24 0.00 $22,754,555
VIT Vitura Health Ltd 0.34 24.07 -51.45 0.00 -1.47 $205,916,866
DTZ Dotz Nano Ltd 0.24 -22.95 -12.96 14.63 -2.08 $108,424,057
EMD Emyria Limited 0.13 -54.39 -31.58 -21.21 -3.70 $41,627,157
NTI Neurotech Intl 0.05 -10.91 -37.18 -9.26 -3.92 $42,821,565
AGH Althea Group 0.05 -62.40 -28.79 -18.97 -6.00 $17,580,082
MXC Mgc Pharmaceuticals 0.01 -67.39 -42.31 -31.82 -6.25 $23,447,851
ALA Arovella Therapeutic 0.07 80.82 175.00 -16.46 -8.33 $51,598,235
BOD BOD Science Ltd 0.05 -65.54 -48.48 -17.74 -10.53 $7,809,196
AVE Avecho Biotech Ltd 0.00 -75.00 -55.56 -20.00 -11.11 $8,648,637
SCU Stemcell United Ltd 0.00 -73.42 -73.42 -30.00 -30.00 $4,496,554
Wordpress Table Plugin

Little Green Pharma (ASX:LGP)

Cannabis stock Little Green Pharma has been reappointed as a primary supplier of its 1:20 THC:CBD medicinal cannabis oil to the extended French national medicinal cannabis trial.

The announcement has reaffirmed LGP’s commitment to France, one of the largest EU markets critical to LGP’s EU strategy – giving LGP a first mover advantage in the country.

To date, LGP has supplied its 1:20 THC:CBD and CBD50 oils to patients in the trial, becoming a well-recognised supplier in the French market in the process.

Following the trial’s initial success, the French government has proposed to extend the trial for a third year, until March 2024.


Epsilon Healthcare (ASX:EPN)

Epsilon surged after announcing that the Medicinal Cannabis Permit issued to its subsidiary, THC Pharma, has been successfully renewed.

In addition, the Australian Office of Drug Control has granted the company increased manufacturing quantities to meet the growing demand.

Epsilon says it has seen a ramp-up in activities, which reflects the changing needs of the industry and client demand.

The company owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere (the Southport, Queensland facility).


Creso Pharma (ASX:CPH) 

Creso has continued to advance its footprint across the Asia Pacific region after expanding its product ranging agreement with  leading Singaporean pet care distributor, Gotro Global.

The expansion deal will see Creso’s entire Green Goo animal care range stocked online through Gotro’s partner company, Happy Town Pets, a specialist ecommerce platform.

Happy Town Pets has an established client base, and is a significant distribution channel for pet care products in Singapore.

This agreement is expected to increase Creso Pharma’s presence in the growing Singaporean pet care industry, and provide additional exposure for the Green Goo brand outside of the US.


At Stockhead we tell it like it is. While Creso Pharma is a Stockhead advertiser, it did not sponsor this article.